The Results of Minimally Invasive Implantation of the HeartMate 3 LVAD Left Ventricular Assist Device

To evaluate the safety, feasibility and effectiveness of minimally invasive HeartMate 3 LVAD implantation.

Forty-seven patients who underwent the HeartMate 3 LVAD implantation by sternotomy and 26 ones who had implantation via minimally invasive method were analyzed. The observation lasted from November 2016 to May 2020.

ECMO as a bridge to LVAD, was more usual in the sternotomy group (11% vs 0%, P = .03). In the minimally invasive group, a history of previous cardiac surgery was more common (54% vs 12%, P < .001), this was the main indication for a minimally invasive approach in our institution. Patients undergoing a minimally invasive implantation had a significantly longer duration of surgery (Med. = 367.5 min vs Med. = 265.0 minutes, P < .001), and significantly higher intraoperative use of fresh frozen plasma (FFP) and platelet concentrates (PCs). There was no significant difference in the number of postoperative bleedings requiring surgical intervention. Postoperative wound infections were observed significantly more often in the sternotomy group (6% vs 0.0%, P < .001). There was no significant difference in survival between groups in the first 180 days after surgery. A slightly lower percentage of patients reached 2-year postsurgery survival in the group undergoing sternotomy, but this finding was not statistically significant. The mean survival time among sternotomy patients was 430.0 days (+/- 291.77 days) vs 633.15 days (+/- 426.84) in minimally invasive group.

Minimally invasive implantation of the HeartMate 3 LVAD may be an alternative method of LVAD implantation in a selected group of patients.